Table 2. Effects of NHI compounds, gemcitabine and their combination on cell cycle.
| Cells | Treatments | G0/G1 Phase (%) | S Phase (%) | G2/M Phase (%) |
|---|---|---|---|---|
| PANC-1 normoxia |
Control |
50.5±1.4 |
26.5±1.1 |
23.0±1.0 |
| Gemcitabine | 43.5±2.5 | 29.8±2.6 | 26.7±3.4 | |
| NHI-1 | 38.9±19 | 33.9±0.8 | 27.2±2.0 | |
| NHI-1+Gemcitabine | 35.9±3.6 | 34.6±2.1 | 29.6±2.2 | |
| NHI-2 | 37.4±3.1 | 32.0±1.7 | 30.6±2.3 | |
| |
NHI-2+Gemcitabine |
36.9±2.8 |
33.3±1.6 |
29.8±2.1 |
| PANC-1 hypoxia |
Control |
62.4±3.2 |
13.3±0.4 |
24.3±2.4 |
| Gemcitabine | 59.9±4.1 | 14.5±1.2 | 26.2±1.7 | |
| NHI-1 | 43.1±2.2 | 33.9±1.3 | 22.9±2.5 | |
| NHI-1+Gemcitabine | 38.2±1.8 | 35.5±1.7 | 26.3±1.7 | |
| NHI-2 | 40.1±1.9 | 32.9±2.5 | 26.9±2.1 | |
| |
NHI-2+Gemcitabine |
39.5±1.3 |
34.3±1.2 |
26.2±1.1 |
| LPC006 normoxia |
Control |
55.4±2.3 |
22.8±1.6 |
21.8±0.9 |
| Gemcitabine | 38.3±1.5 | 30.1±1.1 | 31.6±2.4 | |
| NHI-1 | 36.4±2.7 | 35.2±2.4 | 28.4±1.6 | |
| NHI-1+Gemcitabine | 35.9±1.5 | 34.6±1.2 | 29.6±8.5 | |
| NHI-2 | 37.8±3.2 | 34.2±1.8 | 28.0±3.3 | |
| |
NHI-2+Gemcitabine |
35.9±1.9 |
34.6±1.9 |
29.6±2.4 |
| LPC006 hypoxia |
Control |
63.5±3.8 |
17.2±2.0 |
19.3±1.97 |
| Gemcitabine | 61.1±2.8 | 18.5±0.9 | 20.4±2.1 | |
| NHI-1 | 43.6±1.4 | 33.7±1.7 | 22.7±1.9 | |
| NHI-1+Gemcitabine | 39.8±3.9 | 36.7±1.8 | 23.5±2.2 | |
| NHI-2 | 44.5±3.1 | 31.9±2.1 | 23.6±2.2 | |
| NHI-2+Gemcitabine | 40.9±3.4 | 35.5±3.2 | 23.6±1.2 |
Note: cells were exposed to IC50 values of gemcitabine, 1 (in hypoxia) or 10 μM (in normoxia) NHI compounds, and their combination, for 72 h.